Maybe mgt doesn't feel a need for a follow up PR at this point as the results firmed up the remaining loose ends for a collaboration of some sort with a major BP?

With Dr Menon seeming to be backing off research a bit, it may be that Kevetrin is finally going to be able to be given the full treatment of increased trials and resources from a BP and testing with other cancer treatments in combo trials to make its mark in the world of cancer.

Must be a real tug of war for mgt in considering the pros and cons of doing it themselves or merging efforts with larger partners that bring so many further physical, human, and financial assets to the table.

Great to see another excellent poster come over here in Dauber, quite a valuable addition.